BioGaia Newsletter June 2009

New study on eczema and L. reuteri
Observed effects in a study presented by Nils Gromert, Sweden at ESPGHAN 2009, provide evidence that long-term exposure to Lactobacillus reuteri may be beneficial in the long-term control of eczema.
Fifty children aged 3-47 months with moderate to severe atopic dermatitis were randomised to receive either Lactobacillus reuteri drops or placebo for 12 months. SCORAD, IgE, skin prick test and use of steroids were followed during the study.
Read more

Agreement with InfectoPharm Germany
"InfectoPharm has a strong position and recognition among pediatricians making them an ideal partner for our top selling BioGaia Drops, and we are now confident and eager to take on the challenging German market", says Peter Rothschild, President, BioGaia AB.
InfectoPharm is a German pharmaceutical company with a strong pediatric portfolio.
To InfectoPharm   


Listen to a podcast about probiotics
Dr Andreas Aly, Swedish specialist in Internal Medicine and Gastroenterology, was interviewed about probiotics on the Malaysian business station BFM 98.9 .
The interview is presented into two sections: What is probiotics and what can they do for you? and "Can we obtain this friendly bacteria from food sources; are supplements necessary?"
Listen to the interview

Easy to read about the clinical studies
To date 55 clinical studies on more than 4,100 individuals have been conducted with Lactobacillus reuteri, and results are published in 28 articles in scientific journals. Another 13 studies are published as abstracts of presentations at scientific conferences.
There are summaries made of the studies which you can download from the BioGaia website.
Download the summaries
To Research, BioGaia website

• Unsubscribe
• Newsletter archive
• Contact us